Focal Therapy for Prostate Cancer: Treating Part of the Gland

If you have recently been diagnosed with prostate cancer, you have probably been shown two doors. Behind one is whole-gland treatment — surgery to remove the prostate, or radiation to treat all of it. Behind the other is active surveillance — no treatment now, and careful watching. Focal therapy, also called focal ablation, is the question in between: if the cancer occupies one part of the prostate, can we destroy that part and leave the rest of the gland, and the nerves beside it, alone?

The appeal is obvious. The prostate sits against the nerves that control erections and beneath the muscles that control urine. Whole-gland treatment puts all of that in the treatment field, which is why erectile and urinary side effects are its best-known costs. Focal therapy exists to shrink the treatment field — to trade some of that risk away by treating less.

The honest part is what this page is for: focal therapy only makes sense for some cancers, and the evidence behind it is younger than the evidence behind surgery and radiation. Both of those sentences matter. A clinic that tells you only the first is selling; a page that told you only the second would be hiding an option that, for the right man, is a genuinely reasonable choice.

One more thing, because many men reach this page searching for an “alternative prostate cancer treatment”: focal therapy is an alternative to whole-gland surgery and radiation — it is not alternative medicine. It uses the same MRI, the same targeted biopsy, and the same operating-room technology as the rest of modern urology, aimed at less of the gland. If what you are looking for is a way to treat cancer with supplements or diet instead of medicine, we will be straight with you: no such treatment has been shown to control prostate cancer.

Which rung is yours is decided by the map of your cancer — stage, grade, and where it sits in the gland — not by which rung sounds best. Building that map is what the diagnosis process is for.

Focal therapy is genuinely promising, and it is genuinely less proven than the alternatives. Here is that sentence unpacked, because you will not find it unpacked on most pages about this treatment.

The guideline calls it investigational — and asks us to tell you so

The American Urological Association and ASTRO, in their joint guideline on localized prostate cancer, direct clinicians to inform patients that whole-gland or focal ablation remains investigational without high-quality data comparing ablation outcomes to standard-of-care therapies such as surgery, radiation and active surveillance. For high-risk cancer, the guideline says ablation should not be recommended at all outside a clinical trial. A 2025 systematic review of fifty prospective studies puts it similarly: focal therapies are recommended within registries or trials rather than as settled standard care.

We are telling you that on our own page about the treatment, before you ever sit down, because the alternative is letting you discover it later.

Prostate cancer is often multifocal

Unlike a single lump in a breast, prostate cancer frequently exists in more than one place in the gland, and MRI — good as it is — does not see everything. Focal therapy bets that the significant disease is where the imaging and biopsy say it is, and that anything left behind is the kind best watched rather than treated. For well-selected men that is a reasonable bet. It is also exactly why selection is everything, and why the untreated gland is never simply declared cured.

Treated is not done

After focal therapy you still have a prostate — which means you still have surveillance: PSA testing on a schedule, MRI, and repeat biopsy when anything moves. Your PSA will not fall the way it does after the whole gland is removed, so interpreting it takes judgment and continuity of care. And a second treatment — further ablation, or whole-gland surgery or radiation — is a real possibility we plan for from the start, rather than a failure sprung on you later.

First-line treatment and salvage are different conversations

Ablation as the first treatment for a newly diagnosed cancer, and ablation to rescue a cancer that has returned after radiation, carry different evidence and different risks. Dr. Robbins performs both, and which one applies to you changes the discussion substantially — so we have it explicitly rather than letting one stand in for the other.

If, after all of that, focal therapy still fits your cancer — and the next section is about whether it does — it is not a consolation prize or a compromise. It is a deliberate choice to match the size of the treatment to the size of the problem.

“Focal therapy” names a strategy, not a machine, and more than one energy source can carry it out. In this practice the focal work is done with cryoablation — freezing. That distinction is worth stating plainly, because both of the ablation technologies we offer are sometimes described loosely as “focal.”

Cryoablation — the focal option

Thin probes are placed into the prostate under ultrasound guidance, and argon gas forms a precisely shaped ball of ice around the target tissue while a warming catheter protects the urethra. When the disease is confined to one region, the freeze can be limited to that region rather than the whole gland — which is what makes cryoablation the technology we use when focal treatment is the right call. How the procedure works, what recovery looks like and its role after failed radiation are covered on our cryotherapy page.

HIFU — offered here as whole-gland treatment

High-intensity focused ultrasound concentrates sound waves to heat and destroy prostate tissue with no incision. Dr. Robbins offers HIFU to selected patients, but as a whole-gland treatment rather than a focal one — so if you have read that HIFU can be delivered focally elsewhere, that is true of the technology and not of how it is used here. Sonablate, the system used for prostate HIFU, is FDA-cleared for the ablation of prostate tissue; that is not the same as an approval for the treatment of prostate cancer, and no HIFU system holds such an approval. The device and the procedure are covered on our HIFU page.

Which approach suits which man is an anatomy question, not a ranking. It depends on where the tumor sits, the size and shape of the gland, and your treatment history — a conversation had over your MRI images rather than a menu you order from.

Here is why the candidacy answer you get in this office is worth something: we offer every rung of the ladder. Active surveillance is managed here. Robotic prostatectomy is performed by Dr. Robbins. Radiation is coordinated with radiation oncology, with us remaining your urologist throughout. Cryoablation — focal or whole-gland — and HIFU are both performed by Dr. Robbins.

A clinic that owns one machine tends to find that every man is a candidate for that machine. When the same urologist offers the whole ladder, “you are a candidate” and “you are not” are clinical judgments rather than sales positions — and we say both, regularly.

The selection work happens under the same roof as the treatment. The PSA conversation, the MRI review, and the targeted fusion biopsy that maps exactly where your cancer sits — the map focal therapy lives or dies by — are Dr. Robbins’ own workup, not a referral chain with your chart passed along it.

David Robbins, MD is a board-certified urologist and a Diplomate of the American Board of Urology, in practice at Urological Consultants of Florida since 2009 — a practice that has served South Florida for more than four decades. Our office is on Biscayne Boulevard in North Miami, minutes from Aventura.